1
|
A R Oliveira G, G D V Morales B, M O Sousa R, S Pereira S, Antunes D, Caffarena ER, Zanchi FB. Exploring Novel Antimalarial Compounds Targeting Plasmodium falciparum Enoyl-ACP Reductase: Computational and Experimental Insights. ACS OMEGA 2024; 9:22777-22793. [PMID: 38826533 PMCID: PMC11137734 DOI: 10.1021/acsomega.3c09893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 04/06/2024] [Accepted: 04/15/2024] [Indexed: 06/04/2024]
Abstract
Malaria, caused by Plasmodium protozoa with Plasmodium falciparum as the most virulent species, continues to pose significant health challenges. Despite the availability of effective antimalarial drugs, the emergence of resistance has heightened the urgency for developing novel therapeutic compounds. In this study, we investigated the enoyl-ACP reductase enzyme of P. falciparum (PfENR) as a promising target for antimalarial drug discovery. Through a comprehensive analysis, we conducted a comparative evaluation of two lead compounds, LD1 (CID: 44405336, lead compounds 1) and LD2 (CID: 72703246, lead compounds 2), obtained from the PubChem/NCBI ligand database, to serve as reference molecules in the identification of potential derivatives using virtual screening assays. Among the newly identified candidates, Ligand 1 (LG1) and Ligand 2 (LG2) exhibited intriguing characteristics and underwent further investigation through docking and molecular dynamics simulations. Ligand 1 (LG1) demonstrated interactions similar to LD1, including hydrogen bonding with Asp218, while Ligand 2 (LG2) displayed superior binding energy comparable to LD1 and LD2, despite lacking hydrogen bonding interactions observed in the control compounds triclosan and its derivative 7-(4-chloro-2-hydroxyphenoxy)-4-methyl-2H-chromen-2-one (CHJ). Following computational validation using the MM/GBSA method to estimate binding free energy, commercially acquired LG1 and LG2 ligands were subjected to in vitro testing. Inhibition assays were performed to evaluate their potential as PfENR inhibitors alongside triclosan as a control compound. LG1 exhibited no inhibitory effects, while LG2 demonstrated inhibitory effects like triclosan. In conclusion, this study contributes valuable insights into developing novel antimalarial drugs by identifying LG2 as a potential ligand and employing a comprehensive approach integrating computational and experimental methodologies.
Collapse
Affiliation(s)
- George A R Oliveira
- Laboratório
de Bioinformática e Química Medicinal, Fundação Oswaldo Cruz, CEP: 76812-245 Porto Velho-RO, Brazil
- Programa
de Pós-graduação Stricto sensu em Biologia Computacional
e Sistemas do Instituto Oswaldo Cruz, CEP: 21040-360 Rio de Janeiro-RJ, Brazil
| | - Bruno G D V Morales
- Laboratório
de Bioinformática e Química Medicinal, Fundação Oswaldo Cruz, CEP: 76812-245 Porto Velho-RO, Brazil
- Programa
de Pós-Graduação em Biologia Experimental, Fundação Universidade Federal de Rondônia
(UNIR), CEP: 76801-974 Porto Velho-RO, Brazil
| | - Rosa M O Sousa
- Laboratório
de Engenharia de Anticorpos, Fundação
Oswaldo Cruz de Rondônia, CEP: 76812-245 Porto Velho-RO, Brazil
| | - Soraya S Pereira
- Programa
de Pós-Graduação em Biologia Experimental, Fundação Universidade Federal de Rondônia
(UNIR), CEP: 76801-974 Porto Velho-RO, Brazil
- Laboratório
de Engenharia de Anticorpos, Fundação
Oswaldo Cruz de Rondônia, CEP: 76812-245 Porto Velho-RO, Brazil
- Programa
de Pós-graduação Stricto sensu em Biologia Computacional
e Sistemas do Instituto Oswaldo Cruz, CEP: 21040-360 Rio de Janeiro-RJ, Brazil
| | - Deborah Antunes
- Laboratório
de Genômica Aplicada e Bioinovações, Instituto Oswaldo Cruz, Fundação Oswaldo
Cruz (FIOCRUZ), CEP: 21040-900 Rio de Janeiro-RJ, Brazil
| | - Ernesto R. Caffarena
- Programa
de Pós-graduação Stricto sensu em Biologia Computacional
e Sistemas do Instituto Oswaldo Cruz, CEP: 21040-360 Rio de Janeiro-RJ, Brazil
- Programa
de Computação Científica—PROCC, Fundação
Oswaldo Cruz, CEP: 21040-900 Rio de Janeiro-RJ, Brazil
| | - Fernando B. Zanchi
- Laboratório
de Bioinformática e Química Medicinal, Fundação Oswaldo Cruz, CEP: 76812-245 Porto Velho-RO, Brazil
- Programa
de Pós-Graduação em Biologia Experimental, Fundação Universidade Federal de Rondônia
(UNIR), CEP: 76801-974 Porto Velho-RO, Brazil
- Instituto
Nacional de Epidemiologia na Amazônia Ocidental—EPIAMO, CEP: 76812-245 Porto Velho-RO, Brazil
- Programa
de Pós-graduação Stricto sensu em Biologia Computacional
e Sistemas do Instituto Oswaldo Cruz, CEP: 21040-360 Rio de Janeiro-RJ, Brazil
| |
Collapse
|
2
|
Yadav S, Mandal H, Saravanan V, Das P, Singh SK. In vitro and in silico analysis of L. donovani enoyl acyl carrier protein reductase - A possible drug target. J Biomol Struct Dyn 2020; 39:6056-6069. [PMID: 32762412 DOI: 10.1080/07391102.2020.1802337] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The emergence of increased resistance to the available drugs has created a situation that demands to find out more specific molecular drug targets for Leishmaniasis. The enoyl acyl carrier protein reductase (ENR), a regulatory enzyme in type II fatty acid synthesis, was confirmed as a novel drug target and triclosan as its specific inhibitor in many microorganisms. In this study, the triclosan was tested for the leishmanicidal property against Leishmania donovani (L. donovani) and the results of in vitro and ex vivo drug assays on promastigotes and amastigotes showed that triclosan possessed antileishmanial activity with a half minimal inhibitory concentration (IC50) of 30 µM. Consequently, adopting in silico approach, we have tested the triclosan's ability to bind with the L. donovani enoyl acyl carrier protein reductase (LdENR). The 3D structure of LdENR was modelled, triclosan and cofactors were docked in LdENR model and molecular dynamic simulations were performed to observe the protein-ligands interactions, stability, compactness and binding energy calculation of the ligands-LdENR complexes. The observation showed that triclosan stably interacted with LdENR in presence of both the cofactors (NADPH and NADH), however, simulation results favor NADH as a preferred co-factor for LdENR. These results support that the reduction of L. donovani growth in the in vitro and ex vivo drug assays may be due to the interaction of triclosan with LdENR, which should be confirmed through enzymatic assays. The results of this study suggest that LdENR could be a potential drug target and triclosan as a lead for Leishmaniasis.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Shalini Yadav
- Department of Microbiology, Rajendra Memorial Research Institute of Medical Sciences, ICMR, Patna, India
| | - Haraprasad Mandal
- Department of Microbiology, Rajendra Memorial Research Institute of Medical Sciences, ICMR, Patna, India.,Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, India
| | - Vijayakumar Saravanan
- Division of Bioinformatics, Rajendra Memorial Research Institute of Medical Sciences, ICMR, Patna, India
| | - Pradeep Das
- Division of Molecular Biology, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), ICMR, Patna, India
| | - Shubhankar Kumar Singh
- Department of Microbiology, Rajendra Memorial Research Institute of Medical Sciences, ICMR, Patna, India
| |
Collapse
|
3
|
Limongelli V. Ligand binding free energy and kinetics calculation in 2020. WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL MOLECULAR SCIENCE 2020. [DOI: 10.1002/wcms.1455] [Citation(s) in RCA: 50] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Vittorio Limongelli
- Faculty of Biomedical Sciences, Institute of Computational Science – Center for Computational Medicine in Cardiology Università della Svizzera italiana (USI) Lugano Switzerland
- Department of Pharmacy University of Naples “Federico II” Naples Italy
| |
Collapse
|
4
|
Reduced Susceptibility to Antiseptics Is Conferred by Heterologous Housekeeping Genes. Microb Drug Resist 2018; 24:105-112. [DOI: 10.1089/mdr.2017.0105] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
5
|
Martins-Duarte ÉS, Carias M, Vommaro R, Surolia N, de Souza W. Apicoplast fatty acid synthesis is essential for pellicle formation at the end of cytokinesis in Toxoplasma gondii. J Cell Sci 2016; 129:3320-31. [PMID: 27457282 DOI: 10.1242/jcs.185223] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Accepted: 07/19/2016] [Indexed: 01/19/2023] Open
Abstract
The apicomplexan protozoan Toxoplasma gondii, the causative agent of toxoplasmosis, harbors an apicoplast, a plastid-like organelle with essential metabolic functions. Although the FASII fatty acid biosynthesis pathway located in the apicoplast is essential for parasite survival, the cellular effects of FASII disruption in T. gondii had not been examined in detail. Here, we combined light and electron microscopy techniques - including focused ion beam scanning electron microscopy (FIB-SEM) - to characterize the effect of FASII disruption in T. gondii, by treatment with the FASII inhibitor triclosan or by inducible knockdown of the FASII component acyl carrier protein. Morphological analyses showed that FASII disruption prevented cytokinesis completion in T. gondii tachyzoites, leading to the formation of large masses of 'tethered' daughter cells. FIB-SEM showed that tethered daughters had a mature basal complex, but a defect in new membrane addition between daughters resulted in incomplete pellicle formation. Addition of exogenous fatty acids to medium suppressed the formation of tethered daughter cells and supports the notion that FASII is essential to generate lipid substrates required for the final step of parasite division.
Collapse
Affiliation(s)
- Érica S Martins-Duarte
- Laboratório de Ultraestrutura Celular Hertha Meyer, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 21.941-902 Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagens, Rio de Janeiro, Brazil, 21.941-902
| | - Maira Carias
- Laboratório de Ultraestrutura Celular Hertha Meyer, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 21.941-902 Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagens, Rio de Janeiro, Brazil, 21.941-902
| | - Rossiane Vommaro
- Laboratório de Ultraestrutura Celular Hertha Meyer, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 21.941-902 Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagens, Rio de Janeiro, Brazil, 21.941-902
| | - Namita Surolia
- Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore, India, 560064
| | - Wanderley de Souza
- Laboratório de Ultraestrutura Celular Hertha Meyer, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 21.941-902 Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagens, Rio de Janeiro, Brazil, 21.941-902
| |
Collapse
|
6
|
Abstract
The drug-target residence time model was first introduced in 2006 and has been broadly adopted across the chemical biology, biotechnology and pharmaceutical communities. While traditional in vitro methods view drug-target interactions exclusively in terms of equilibrium affinity, the residence time model takes into account the conformational dynamics of target macromolecules that affect drug binding and dissociation. The key tenet of this model is that the lifetime (or residence time) of the binary drug-target complex, and not the binding affinity per se, dictates much of the in vivo pharmacological activity. Here, this model is revisited and key applications of it over the past 10 years are highlighted.
Collapse
|
7
|
González-Thuillier I, Venegas-Calerón M, Garcés R, von Wettstein-Knowles P, Martínez-Force E. Sunflower (Helianthus annuus) fatty acid synthase complex: enoyl-[acyl carrier protein]-reductase genes. PLANTA 2015; 241:43-56. [PMID: 25204631 DOI: 10.1007/s00425-014-2162-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Accepted: 08/22/2014] [Indexed: 05/13/2023]
Abstract
Enoyl-[acyl carrier protein]-reductases from sunflower. A major factor contributing to the amount of fatty acids in plant oils are the first steps of their synthesis. The intraplastidic fatty acid biosynthetic pathway in plants is catalysed by type II fatty acid synthase (FAS). The last step in each elongation cycle is carried out by the enoyl-[ACP]-reductase, which reduces the dehydrated product of β-hydroxyacyl-[ACP] dehydrase using NADPH or NADH. To determine the mechanisms involved in the biosynthesis of fatty acids in sunflower (Helianthus annuus) seeds, two enoyl-[ACP]-reductase genes have been identified and cloned from developing seeds with 75 % identity: HaENR1 (GenBank HM021137) and HaENR2 (HM021138). The two genes belong to the ENRA and ENRB families in dicotyledons, respectively. The genetic duplication most likely originated after the separation of di- and monocotyledons. RT-qPCR revealed distinct tissue-specific expression patterns. Highest expression of HaENR1 was in roots, stems and developing cotyledons whereas that of H a ENR2 was in leaves and early stages of seed development. Genomic DNA gel blot analyses suggest that both are single-copy genes. In vivo activity of the ENR enzymes was tested by complementation experiments with the JP1111 fabI(ts) E. coli strain. Both enzymes were functional demonstrating that they interacted with the bacterial FAS components. That different fatty acid profiles resulted infers that the two Helianthus proteins have different structures, substrate specificities and/or reaction rates. The latter possibility was confirmed by in vitro analysis with affinity-purified heterologous-expressed enzymes that reduced the crotonyl-CoA substrate using NADH with different V max.
Collapse
|
8
|
Integrating molecular docking, CoMFA analysis, and machine-learning classification with virtual screening toward identification of novel scaffolds as Plasmodium falciparum enoyl acyl carrier protein reductase inhibitor. Med Chem Res 2014. [DOI: 10.1007/s00044-014-0910-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
9
|
Afanador GA, Muench SP, McPhillie M, Fomovska A, Schön A, Zhou Y, Cheng G, Stec J, Freundlich JS, Shieh HM, Anderson JW, Jacobus DP, Fidock DA, Kozikowski AP, Fishwick CW, Rice DW, Freire E, McLeod R, Prigge ST. Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry 2013; 52:9155-66. [PMID: 24295325 DOI: 10.1021/bi400945y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Many microbial pathogens rely on a type II fatty acid synthesis (FASII) pathway that is distinct from the type I pathway found in humans. Enoyl-acyl carrier protein reductase (ENR) is an essential FASII pathway enzyme and the target of a number of antimicrobial drug discovery efforts. The biocide triclosan is established as a potent inhibitor of ENR and has been the starting point for medicinal chemistry studies. We evaluated a series of triclosan analogues for their ability to inhibit the growth of Toxoplasma gondii, a pervasive human pathogen, and its ENR enzyme (TgENR). Several compounds that inhibited TgENR at low nanomolar concentrations were identified but could not be further differentiated because of the limited dynamic range of the TgENR activity assay. Thus, we adapted a thermal shift assay (TSA) to directly measure the dissociation constant (Kd) of the most potent inhibitors identified in this study as well as inhibitors from previous studies. Furthermore, the TSA allowed us to determine the mode of action of these compounds in the presence of the reduced nicotinamide adenine dinucleotide (NADH) or nicotinamide adenine dinucleotide (NAD⁺) cofactor. We found that all of the inhibitors bind to a TgENR-NAD⁺ complex but that they differed in their dependence on NAD⁺ concentration. Ultimately, we were able to identify compounds that bind to the TgENR-NAD⁺ complex in the low femtomolar range. This shows how TSA data combined with enzyme inhibition, parasite growth inhibition data, and ADMET predictions allow for better discrimination between potent ENR inhibitors for the future development of medicine.
Collapse
Affiliation(s)
- Gustavo A Afanador
- Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland 21205, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Although drug-target interactions are commonly illustrated in terms of structurally static binding and dissociation events, such descriptions are inadequate to explain the impact of conformational dynamics on these processes. For high-affinity interactions, both the association and dissociation of drug molecules to and from their targets are often controlled by conformational changes of the target. Conformational adaptation can greatly influence the residence time of a drug on its target (i.e., the lifetime of the binary drug-target complex); long residence time can lead to sustained pharmacology and may also mitigate off-target toxicity. In this perspective, the kinetics of drug-target association and dissociation reactions are explored, with particular emphasis on the impact of conformational adaptation on drug-target residence time.
Collapse
|
11
|
Banerjee T, Sharma SK, Kapoor N, Dwivedi V, Surolia N, Surolia A. Benzothiophene carboxamide derivatives as inhibitors of Plasmodium falciparum enoyl-ACP reductase. IUBMB Life 2011; 63:1101-10. [PMID: 22006792 DOI: 10.1002/iub.553] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2011] [Accepted: 07/07/2011] [Indexed: 11/09/2022]
Abstract
Benzothiophene derivatives like benzothiophene sulphonamides, biphenyls, or carboxyls have been synthesized and have found wide pharmacological usage. Here we report, bromo-benzothiophene carboxamide derivatives as potent, slow tight binding inhibitors of Plasmodium enoyl-acyl carrier protein (ACP) reductase (PfENR). 3-Bromo-N-(4-fluorobenzyl)-benzo[b]thiophene-2-carboxamide (compound 6) is the most potent inhibitor with an IC50 of 115 nM for purified PfENR. The inhibition constant (Ki) of compound 6 was 18 nM with respect to the cofactor and 91 nM with respect to crotonoyl-CoA. These inhibitors showed competitive kinetics with cofactor and uncompetitive kinetics with the substrate. Thus, these compounds hold promise for the development of potent antimalarials.
Collapse
|
12
|
de Medeiros PSDM, Ducati RG, Basso LA, Santos DS, da Silva LHP. Enzyme Mechanism and Slow-Onset Inhibition of Plasmodium falciparum Enoyl-Acyl Carrier Protein Reductase by an Inorganic Complex. Enzyme Res 2011; 2011:642758. [PMID: 21603269 PMCID: PMC3092583 DOI: 10.4061/2011/642758] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2010] [Accepted: 01/25/2011] [Indexed: 11/20/2022] Open
Abstract
Malaria continues to be a major cause of children's morbidity and mortality worldwide, causing nearly one million deaths annually. The human malaria parasite, Plasmodium falciparum, synthesizes fatty acids employing the Type II fatty acid biosynthesis system (FAS II), unlike humans that rely on the Type I (FAS I) pathway. The FAS II system elongates acyl fatty acid precursors of the cell membrane in Plasmodium. Enoyl reductase (ENR) enzyme is a member of the FAS II system. Here we present steady-state kinetics, pre-steady-state kinetics, and equilibrium fluorescence spectroscopy data that allowed proposal of P. falciparum ENR (PfENR) enzyme mechanism. Moreover, building on previous results, the present study also evaluates the PfENR inhibition by the pentacyano(isoniazid)ferrateII compound. This inorganic complex represents a new class of lead compounds for the development of antimalarial agents focused on the inhibition of PfENR.
Collapse
|
13
|
Maity K, Banerjee T, Prabakaran N, Surolia N, Surolia A, Suguna K. Effect of substrate binding loop mutations on the structure, kinetics, and inhibition of enoyl acyl carrier protein reductase from Plasmodium falciparum. IUBMB Life 2011; 63:30-41. [PMID: 21280175 DOI: 10.1002/iub.412] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2010] [Accepted: 11/30/2010] [Indexed: 11/06/2022]
Abstract
Enoyl acyl carrier protein reductase (ENR), which catalyzes the final and rate limiting step of fatty acid elongation, has been validated as a potential drug target. Triclosan is known to be an effective inhibitor for this enzyme. We mutated the substrate binding site residue Ala372 of the ENR of Plasmodium falciparum (PfENR) to Methionine and Valine which increased the affinity of the enzyme towards triclosan to almost double, close to that of Escherichia coli ENR (EcENR) which has a Methionine at the structurally similar position of Ala372 of PfENR. Kinetic studies of the mutants of PfENR and the crystal structure analysis of the A372M mutant revealed that a more hydrophobic environment enhances the affinity of the enzyme for the inhibitor. A triclosan derivative showed a threefold increase in the affinity towards the mutants compared to the wild type, due to additional interactions with the A372M mutant as revealed by the crystal structure. The enzyme has a conserved salt bridge which stabilizes the substrate binding loop and appears to be important for the active conformation of the enzyme. We generated a second set of mutants to check this hypothesis. These mutants showed loss of function, except in one case, where the crystal structure showed that the substrate binding loop is stabilized by a water bridge network.
Collapse
Affiliation(s)
- Koustav Maity
- Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India
| | | | | | | | | | | |
Collapse
|
14
|
Maity K, Bhargav SP, Sankaran B, Surolia N, Surolia A, Suguna K. X-ray crystallographic analysis of the complexes of enoyl acyl carrier protein reductase of Plasmodium falciparum with triclosan variants to elucidate the importance of different functional groups in enzyme inhibition. IUBMB Life 2010; 62:467-76. [PMID: 20503440 DOI: 10.1002/iub.327] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Triclosan, a well-known inhibitor of Enoyl Acyl Carrier Protein Reductase (ENR) from several pathogenic organisms, is a promising lead compound to design effective drugs. We have solved the X-ray crystal structures of Plasmodium falciparum ENR in complex with triclosan variants having different substituted and unsubstituted groups at different key functional locations. The structures revealed that 4 and 2' substituted compounds have more interactions with the protein, cofactor, and solvents when compared with triclosan. New water molecules were found to interact with some of these inhibitors. Substitution at the 2' position of triclosan caused the relocation of a conserved water molecule, leading to an additional hydrogen bond with the inhibitor. This observation can help in conserved water-based inhibitor design. 2' and 4' unsubstituted compounds showed a movement away from the hydrophobic pocket to compensate for the interactions made by the halogen groups of triclosan. This compound also makes additional interactions with the protein and cofactor which compensate for the lost interactions due to the unsubstitution at 2' and 4'. In cell culture, this inhibitor shows less potency, which indicates that the chlorines at 2' and 4' positions increase the ability of the inhibitor to cross multilayered membranes. This knowledge helps us to modify the different functional groups of triclosan to get more potent inhibitors.
Collapse
Affiliation(s)
- Koustav Maity
- Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560 012, India
| | | | | | | | | | | |
Collapse
|
15
|
Kapoor N, Banerjee T, Babu P, Maity K, Surolia N, Surolia A. Design, development, synthesis, and docking analysis of 2'-substituted triclosan analogs as inhibitors for Plasmodium falciparum enoyl-ACP reductase. IUBMB Life 2010; 61:1083-91. [PMID: 19859979 DOI: 10.1002/iub.258] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
A structure-based approach has been adopted to develop 2'-substituted analogs of triclosan. The Cl at position 2' in ring B of triclosan was chemically substituted with other functional groups like NH(2), NO(2) and their inhibitory potencies against PfENR were determined. The binding energies of the 2' substituted analogs of triclosan for enoyl-acyl carrier protein reductase (ENR) of Plasmodium falciparum were determined using Autodock. Based on the autodock results, we synthesized the potential compounds. The IC(50) and inhibition constant (K(i)) of 2' substituted analogs of triclosan were determined against purified PfENR. Among them, two compounds, 2-(2'-Amino-4'-chloro-phenoxy)-5-chloro-phenol (compound 4) and 5-chloro-2-(4'-chloro-2'-nitro-phenoxy)-phenol) (compound 5) exhibited good potencies. Compound 4 followed uncompetitive inhibition kinetics with crotonoyl CoA and competitive with NADH. It was shown to have an IC(50) of 110 nM; inhibition constant was 104 nM with the substrate and 61 nM with the cofactor. IC(50) of compound 5 was determined to be 229 nM. Compounds 4 and 5 showed significant inhibition of the parasite growth in P. falciparum culture.
Collapse
Affiliation(s)
- Neha Kapoor
- National Institute of Immunology, Molecular Sciences Laboratory, New Delhi, India
| | | | | | | | | | | |
Collapse
|
16
|
Kumar G, Banerjee T, Kapoor N, Surolia N, Surolia A. SAR and pharmacophore models for the rhodanine inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. IUBMB Life 2010; 62:204-13. [DOI: 10.1002/iub.306] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
17
|
Singh AP, Surolia N, Surolia A. Triclosan inhibit the growth of the late liver-stage ofPlasmodium. IUBMB Life 2009; 61:923-8. [DOI: 10.1002/iub.237] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
18
|
Abstract
The enoyl-acyl carrier protein reductase (ENR) is the last enzyme in the fatty acid elongation cycle. Unlike most enzymes in this essential pathway, ENR displays an unusual diversity among organisms. The growing interest in ENRs is mainly due to the fact that a variety of both synthetic and natural antibacterial compounds are shown to specifically target their activity. The primary anti-tuberculosis drug, isoniazid, and the broadly used antibacterial compound, triclosan, both target this enzyme. In this review, we discuss the diversity of ENRs, and their inhibitors in the light of current research progress.
Collapse
Affiliation(s)
- R. P. Massengo-Tiassé
- Departments of Microbiology, B103, Chemical and Life Sciences Laboratory, University of Illinois at Urbana-Champaign, 601 S. Goodwin Ave, Urbana, IL 61801 USA
| | - J. E. Cronan
- Departments of Microbiology, B103, Chemical and Life Sciences Laboratory, University of Illinois at Urbana-Champaign, 601 S. Goodwin Ave, Urbana, IL 61801 USA
- Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801 USA
| |
Collapse
|
19
|
De Crescenzo G, Boucher C, Durocher Y, Jolicoeur M. Kinetic Characterization by Surface Plasmon Resonance-Based Biosensors: Principle and Emerging Trends. Cell Mol Bioeng 2008. [DOI: 10.1007/s12195-008-0035-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
20
|
Banerjee T, Sharma SK, Surolia N, Surolia A. Epigallocatechin gallate is a slow-tight binding inhibitor of enoyl-ACP reductase from Plasmodium falciparum. Biochem Biophys Res Commun 2008; 377:1238-42. [DOI: 10.1016/j.bbrc.2008.10.135] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2008] [Accepted: 10/28/2008] [Indexed: 01/19/2023]
|
21
|
Karmodiya K, Modak R, Sahoo N, Sajad S, Surolia N. Deciphering the key residues in Plasmodium falciparum beta-ketoacyl acyl carrier protein reductase responsible for interactions with Plasmodium falciparum acyl carrier protein. FEBS J 2008; 275:4756-66. [PMID: 18721141 DOI: 10.1111/j.1742-4658.2008.06608.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The type II fatty acid synthase (FAS) pathway of Plasmodium falciparum is a validated unique target for developing novel antimalarials, due to its intrinsic differences from the typeI pathway operating in humans. beta-Ketoacyl acyl carrier protein (ACP) reductase (FabG) performs the NADPH-dependent reduction of beta-ketoacyl-ACP to beta-hydroxyacyl-ACP, the first reductive step in the elongation cycle of fatty acid biosynthesis. In this article, we report intensive studies on the direct interactions of Plasmodium FabG and Plasmodium ACP in solution, in the presence and absence of its cofactor, NADPH, by monitoring the change in intrinsic fluorescence of P.falciparum FabG (PfFabG) and by surface plasmon resonance. To address the issue of the importance of the residues involved in strong, specific and stoichiometric binding of PfFabG to P.falciparum ACP (PfACP), we mutated Arg187, Arg190 and Arg230 of PfFabG. The activities of the mutants were assessed using both an ACP-dependent and an ACP-independent assay. The affinities of all the PfFabG mutants for acetoacetyl-ACP (the physiological substrate) were reduced to different extents as compared to wild-type PfFabG, but were equally active in biochemical assays with the substrate analog acetoacetyl-CoA. Kinetic analysis and studies of direct binding between PfFabG and PfACP confirmed the identification of Arg187 and Arg230 as critical residues for the PfFabG-PfACP interactions. Our studies thus reveal the significance of the positively charged/hydrophobic patch located adjacent to the active site cavities of PfFabG for interactions with PfACP.
Collapse
Affiliation(s)
- Krishanpal Karmodiya
- Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore, India
| | | | | | | | | |
Collapse
|
22
|
Tipparaju SK, Mulhearn DC, Klein GM, Chen Y, Tapadar S, Bishop MH, Yang S, Chen J, Ghassemi M, Santarsiero BD, Cook JL, Johlfs M, Mesecar AD, Johnson ME, Kozikowski AP. Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase. ChemMedChem 2008; 3:1250-68. [PMID: 18663709 PMCID: PMC2693028 DOI: 10.1002/cmdc.200800047] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2008] [Indexed: 11/11/2022]
Abstract
The problem of increasing bacterial resistance to the current generation of antibiotics is well documented. Known resistant pathogens such as methicillin-resistant Staphylococcus aureus are becoming more prevalent, while the potential exists for developing drug-resistant pathogens for use as bioweapons, such as Bacillus anthracis. The biphenyl ether antibacterial agent, triclosan, exhibits broad-spectrum activity by targeting the fatty acid biosynthetic pathway through inhibition of enoyl-acyl carrier protein reductase (ENR) and provides a potential scaffold for the development of new, broad-spectrum antibiotics. We used a structure-based approach to develop novel aryl ether analogues of triclosan that target ENR, the product of the fabI gene, from B. anthracis (BaENR). Structure-based design methods were used for the expansion of the compound series including X-ray crystal structure determination, molecular docking, and QSAR methods. Structural modifications were made to both phenyl rings of the 2-phenoxyphenyl core. A number of compounds exhibited improved potency against BaENR and increased efficacy against both the Sterne strain of B. anthracis and the methicillin-resistant strain of S. aureus. X-ray crystal structures of BaENR in complex with triclosan and two other compounds help explain the improved efficacy of the new compounds and suggest future rounds of optimization that might be used to improve their potency.
Collapse
Affiliation(s)
- Suresh K. Tipparaju
- Dr. S. K. Tipparaju, Dr. Y. Chen, Dr. S. Tapadar, Prof. Dr. A. P. Kozikowski, Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 S. Wood St., Chicago, IL 60612, USA Fax: (312) 413 0577
| | - Debbie C. Mulhearn
- Dr. D. C. Mulhearn, G. M. Klein, M. H. Bishop, S. Yang, Dr. B. D. Santarsiero, Dr. M. Johlfs, Dr. A. D. Mesecar, Prof. Dr. M. E. Johnson, Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 S. Ashland Ave., Chicago, IL 60607–7173, USA, Fax: (312) 413 9303
| | - Gary M. Klein
- Dr. S. K. Tipparaju, Dr. Y. Chen, Dr. S. Tapadar, Prof. Dr. A. P. Kozikowski, Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 S. Wood St., Chicago, IL 60612, USA Fax: (312) 413 0577
- Dr. D. C. Mulhearn, G. M. Klein, M. H. Bishop, S. Yang, Dr. B. D. Santarsiero, Dr. M. Johlfs, Dr. A. D. Mesecar, Prof. Dr. M. E. Johnson, Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 S. Ashland Ave., Chicago, IL 60607–7173, USA, Fax: (312) 413 9303
| | - Yufeng Chen
- Dr. S. K. Tipparaju, Dr. Y. Chen, Dr. S. Tapadar, Prof. Dr. A. P. Kozikowski, Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 S. Wood St., Chicago, IL 60612, USA Fax: (312) 413 0577
| | - Subhasish Tapadar
- Dr. S. K. Tipparaju, Dr. Y. Chen, Dr. S. Tapadar, Prof. Dr. A. P. Kozikowski, Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 S. Wood St., Chicago, IL 60612, USA Fax: (312) 413 0577
| | - Molly H. Bishop
- Dr. D. C. Mulhearn, G. M. Klein, M. H. Bishop, S. Yang, Dr. B. D. Santarsiero, Dr. M. Johlfs, Dr. A. D. Mesecar, Prof. Dr. M. E. Johnson, Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 S. Ashland Ave., Chicago, IL 60607–7173, USA, Fax: (312) 413 9303
| | - Shuo Yang
- Dr. D. C. Mulhearn, G. M. Klein, M. H. Bishop, S. Yang, Dr. B. D. Santarsiero, Dr. M. Johlfs, Dr. A. D. Mesecar, Prof. Dr. M. E. Johnson, Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 S. Ashland Ave., Chicago, IL 60607–7173, USA, Fax: (312) 413 9303
| | - Juan Chen
- Dr. J. Chen, Dr. M. Ghassemi, Dr. J. L. Cook, Department of Medicine, University of Illinois at Chicago, 808 S. Wood St., Chicago IL 60612, USA
| | - Mahmood Ghassemi
- Dr. J. Chen, Dr. M. Ghassemi, Dr. J. L. Cook, Department of Medicine, University of Illinois at Chicago, 808 S. Wood St., Chicago IL 60612, USA
| | - Bernard D. Santarsiero
- Dr. D. C. Mulhearn, G. M. Klein, M. H. Bishop, S. Yang, Dr. B. D. Santarsiero, Dr. M. Johlfs, Dr. A. D. Mesecar, Prof. Dr. M. E. Johnson, Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 S. Ashland Ave., Chicago, IL 60607–7173, USA, Fax: (312) 413 9303
| | - James L. Cook
- Dr. J. Chen, Dr. M. Ghassemi, Dr. J. L. Cook, Department of Medicine, University of Illinois at Chicago, 808 S. Wood St., Chicago IL 60612, USA
| | - Mary Johlfs
- Dr. D. C. Mulhearn, G. M. Klein, M. H. Bishop, S. Yang, Dr. B. D. Santarsiero, Dr. M. Johlfs, Dr. A. D. Mesecar, Prof. Dr. M. E. Johnson, Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 S. Ashland Ave., Chicago, IL 60607–7173, USA, Fax: (312) 413 9303
| | - Andrew D. Mesecar
- Dr. S. K. Tipparaju, Dr. Y. Chen, Dr. S. Tapadar, Prof. Dr. A. P. Kozikowski, Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 S. Wood St., Chicago, IL 60612, USA Fax: (312) 413 0577
- Dr. D. C. Mulhearn, G. M. Klein, M. H. Bishop, S. Yang, Dr. B. D. Santarsiero, Dr. M. Johlfs, Dr. A. D. Mesecar, Prof. Dr. M. E. Johnson, Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 S. Ashland Ave., Chicago, IL 60607–7173, USA, Fax: (312) 413 9303
| | - Michael E. Johnson
- Dr. D. C. Mulhearn, G. M. Klein, M. H. Bishop, S. Yang, Dr. B. D. Santarsiero, Dr. M. Johlfs, Dr. A. D. Mesecar, Prof. Dr. M. E. Johnson, Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 S. Ashland Ave., Chicago, IL 60607–7173, USA, Fax: (312) 413 9303
| | - Alan P. Kozikowski
- Dr. S. K. Tipparaju, Dr. Y. Chen, Dr. S. Tapadar, Prof. Dr. A. P. Kozikowski, Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 S. Wood St., Chicago, IL 60612, USA Fax: (312) 413 0577
| |
Collapse
|
23
|
Mishra S, Karmodiya K, Parasuraman P, Surolia A, Surolia N. Design, synthesis, and application of novel triclosan prodrugs as potential antimalarial and antibacterial agents. Bioorg Med Chem 2008; 16:5536-46. [DOI: 10.1016/j.bmc.2008.04.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2008] [Accepted: 04/04/2008] [Indexed: 10/22/2022]
|
24
|
Freundlich JS, Wang F, Tsai HC, Kuo M, Shieh HM, Anderson JW, Nkrumah LJ, Valderramos JC, Yu M, Kumar TRS, Valderramos SG, Jacobs WR, Schiehser GA, Jacobus DP, Fidock DA, Sacchettini JC. X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy. J Biol Chem 2007; 282:25436-44. [PMID: 17567585 DOI: 10.1074/jbc.m701813200] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The x-ray crystal structures of five triclosan analogs, in addition to that of the isoniazid-NAD adduct, are described in relation to their integral role in the design of potent inhibitors of the malarial enzyme Plasmodium falciparum enoyl acyl carrier protein reductase (PfENR). Many of the novel 5-substituted analogs exhibit low micromolar potency against in vitro cultures of drug-resistant and drug-sensitive strains of the P. falciparum parasite and inhibit purified PfENR enzyme with IC50 values of <200 nM. This study has significantly expanded the knowledge base with regard to the structure-activity relationship of triclosan while affording gains against cultured parasites and purified PfENR enzyme. In contrast to a recent report in the literature, these results demonstrate the ability to improve the in vitro potency of triclosan significantly by replacing the suboptimal 5-chloro group with larger hydrophobic moieties. The biological and x-ray crystallographic data thus demonstrate the flexibility of the active site and point to future rounds of optimization to improve compound potency against purified enzyme and intracellular Plasmodium parasites.
Collapse
Affiliation(s)
- Joel S Freundlich
- Department of Medicinal Chemistry, Jacobus Pharmaceutical Company, Princeton, New Jersey 08540, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Chhibber M, Kumar G, Parasuraman P, Ramya TNC, Surolia N, Surolia A. Novel diphenyl ethers: design, docking studies, synthesis and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli. Bioorg Med Chem 2006; 14:8086-98. [PMID: 16893651 DOI: 10.1016/j.bmc.2006.07.034] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2006] [Revised: 07/16/2006] [Accepted: 07/18/2006] [Indexed: 10/24/2022]
Abstract
We designed some novel diphenyl ethers and determined their binding energies for Enoyl-Acyl Carrier Protein Reductase (ENR) of Plasmodium falciparum using Autodock. Out of these, we synthesized the promising compounds and tested them for their inhibitory activity against ENRs of P. falciparum as well as Escherichia coli. Some of these compounds show nanomolar inhibition of PfENR and low micromolar inhibition of EcENR. They also exhibit low micromolar potency against in vitro cultures of P. falciparum and E. coli. The study of structure-activity relationship of these compounds paves the way for further improvements in the design of novel diphenyl ethers with improved activity against purified enzyme and the pathogens.
Collapse
Affiliation(s)
- Manmohan Chhibber
- Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560012, India
| | | | | | | | | | | |
Collapse
|
26
|
Swarnamukhi PL, Sharma SK, Bajaj P, Surolia N, Surolia A, Suguna K. Crystal structure of dimeric FabZ ofPlasmodium falciparumreveals conformational switching to active hexamers by peptide flips. FEBS Lett 2006; 580:2653-60. [PMID: 16643907 DOI: 10.1016/j.febslet.2006.04.014] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2006] [Revised: 03/21/2006] [Accepted: 04/04/2006] [Indexed: 10/24/2022]
Abstract
The crystal structure of beta-hydroxyacyl acyl carrier protein dehydratase of Plasmodium falciparum (PfFabZ) has been determined at a resolution of 2.4 A. PfFabZ has been found to exist as a homodimer (d-PfFabZ) in the crystals of the present study in contrast to the reported hexameric form (h-PfFabZ) which is a trimer of dimers crystallized in a different condition. The catalytic sites of this enzyme are located in deep narrow tunnel-shaped pockets formed at the dimer interface. A histidine residue from one subunit of the dimer and a glutamate residue from the other subunit lining the tunnel form the catalytic dyad in the reported crystal structures. While the position of glutamate remains unaltered in the crystal structure of d-PfFabZ compared to that in h-PfFabZ, the histidine residue takes up an entirely different conformation and moves away from the tunnel leading to a His-Phe cis-trans peptide flip at the histidine residue. In addition, a loop in the vicinity has been observed to undergo a similar flip at a Tyr-Pro peptide bond. These alterations not only prevent the formation of a hexamer but also distort the active site geometry resulting in a dimeric form of FabZ that is incapable of substrate binding. The dimeric state and an altered catalytic site architecture make d-PfFabZ distinctly different from the FabZ structures described so far. Dynamic light scattering and size exclusion chromatographic studies clearly indicate a pH-related switching of the dimers to active hexamers.
Collapse
|
27
|
Freundlich JS, Yu M, Lucumi E, Kuo M, Tsai HC, Valderramos JC, Karagyozov L, Jacobs WR, Schiehser GA, Fidock DA, Jacobus DP, Sacchettini JC. Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan derivatives. Bioorg Med Chem Lett 2006; 16:2163-9. [PMID: 16466916 DOI: 10.1016/j.bmcl.2006.01.051] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2005] [Revised: 01/13/2006] [Accepted: 01/13/2006] [Indexed: 10/25/2022]
Abstract
2'-Substituted analogs of triclosan have been synthesized to target inhibition of the key malarial enzyme Plasmodium falciparum enoyl acyl carrier protein reductase (PfENR). Many of these compounds exhibit good potency (EC50<500 nM) against in vitro cultures of drug-resistant and drug-sensitive strains of the P. falciparum parasite and modest (IC50=1-20 microM) potency against purified PfENR enzyme. Compared to triclosan, this survey of 2'-substituted derivatives has afforded gains in excess of 20- and 30-fold versus the 3D7 and Dd2 strains of parasite, respectively.
Collapse
Affiliation(s)
- Joel S Freundlich
- Department of Medicinal Chemistry, Jacobus Pharmaceutical Company, 37 Cleveland Lane, Princeton, NJ 08540, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Freundlich JS, Anderson JW, Sarantakis D, Shieh HM, Yu M, Valderramos JC, Lucumi E, Kuo M, Jacobs WR, Fidock DA, Schiehser GA, Jacobus DP, Sacchettini JC. Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives. Bioorg Med Chem Lett 2005; 15:5247-52. [PMID: 16198563 DOI: 10.1016/j.bmcl.2005.08.044] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2005] [Revised: 08/09/2005] [Accepted: 08/17/2005] [Indexed: 11/26/2022]
Abstract
A structure-based approach has been taken to develop 4'-substituted analogs of triclosan that target the key malarial enzyme Plasmodium falciparum enoyl acyl carrier protein reductase (PfENR). Many of these compounds exhibit nanomolar potency against purified PfENR enzyme and modest (2-10microM) potency against in vitro cultures of drug-resistant and drug-sensitive strains of the P. falciparum parasite. X-ray crystal structures of nitro 29, aniline 30, methylamide 37, and urea 46 demonstrate the presence of hydrogen-bonding interactions with residues in the active site and point to future rounds of optimization to improve compound potency against purified enzyme and intracellular parasites.
Collapse
Affiliation(s)
- Joel S Freundlich
- Department of Medicinal Chemistry, Jacobus Pharmaceutical Company, 37 Cleveland Lane, Princeton, NJ 08540, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Sharma SK, Modak R, Sharma S, Sharma AK, Sarma SP, Surolia A, Surolia N. A novel approach for over-expression, characterization, and isotopic enrichment of a homogeneous species of acyl carrier protein from Plasmodium falciparum. Biochem Biophys Res Commun 2005; 330:1019-26. [PMID: 15823545 DOI: 10.1016/j.bbrc.2005.03.094] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2005] [Indexed: 11/22/2022]
Abstract
Acyl carrier protein (ACP) plays a central role in fatty acid biosynthesis by transferring the acyl groups from one enzyme to another for the completion of the fatty acid synthesis cycle. Holo-ACP is the obligatory substrate for the synthesis of acyl-ACPs which act as the carrier and donor for various metabolic reactions. Despite its interactions with numerous proteins in the cell, its mode of interaction is poorly understood. Here, we report the over-expression of PfACP in minimal medium solely in its holo form and in high yield. Expression in minimal media provides a means to isotopically label PfACP for high resolution multi-nuclear and multi-dimensional NMR studies. Indeed, the proton-nitrogen correlated NMR spectrum exhibits very high chemical shift dispersion and resolution. We also show that holo-PfACP thus expressed is amenable to acylation reactions using Escherichia coli acyl-ACP synthetase as well as by standard chemical methods.
Collapse
|
30
|
Abstract
The year 2004 represents a milestone for the biosensor research community: in this year, over 1000 articles were published describing experiments performed using commercially available systems. The 1038 papers we found represent an approximately 10% increase over the past year and demonstrate that the implementation of biosensors continues to expand at a healthy pace. We evaluated the data presented in each paper and compiled a 'top 10' list. These 10 articles, which we recommend every biosensor user reads, describe well-performed kinetic, equilibrium and qualitative/screening studies, provide comparisons between binding parameters obtained from different biosensor users, as well as from biosensor- and solution-based interaction analyses, and summarize the cutting-edge applications of the technology. We also re-iterate some of the experimental pitfalls that lead to sub-optimal data and over-interpreted results. We are hopeful that the biosensor community, by applying the hints we outline, will obtain data on a par with that presented in the 10 spotlighted articles. This will ensure that the scientific community at large can be confident in the data we report from optical biosensors.
Collapse
Affiliation(s)
- Rebecca L Rich
- Center for Biomolecular Interaction Analysis, University of Utah, Salt Lake City, UT 84132, USA
| | | |
Collapse
|
31
|
Kapoor M, Gopalakrishnapai J, Surolia N, Surolia A. Mutational analysis of the triclosan-binding region of enoyl-ACP (acyl-carrier protein) reductase from Plasmodium falciparum. Biochem J 2004; 381:735-41. [PMID: 15139852 PMCID: PMC1133883 DOI: 10.1042/bj20040302] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2004] [Revised: 04/15/2004] [Accepted: 05/13/2004] [Indexed: 11/17/2022]
Abstract
Triclosan, a known antibacterial, acts by inhibiting enoyl-ACP (acyl-carrier protein) reductase (ENR), a key enzyme of the type II fatty acid synthesis (FAS) system. Plasmodium falciparum, the human malaria-causing parasite, harbours the type II FAS; in contrast, its human host utilizes type I FAS. Due to this striking difference, ENR has emerged as an important target for the development of new antimalarials. Modelling studies, and the crystal structure of P. falciparum ENR, have highlighted the features of ternary complex formation between the enzyme, triclosan and NAD+ [Suguna, A. Surolia and N. Surolia (2001) Biochem. Biophys. Res. Commun. 283, 224-228; Perozzo, Kuo, Sidhu, Valiyaveettil, Bittman, Jacobs, Fidock, and Sacchettini (2002) J. Biol. Chem. 277, 13106-13114; and Swarnamukhi, Kapoor, N. Surolia, A. Surolia and Suguna (2003) PDB1UH5]. To address the issue of the importance of the residues involved in strong specific and stoichiometric binding of triclosan to P. falciparum ENR, we mutated the following residues: Ala-217, Asn-218, Met-281, and Phe-368. The affinity of all the mutants was reduced for triclosan as compared with the wild-type enzyme to different extents. The most significant mutation was A217V, which led to a greater than 7000-fold decrease in the binding affinity for triclosan as compared with wild-type PfENR. A217G showed only 10-fold reduction in the binding affinity. Thus, these studies point out significant differences in the triclosan-binding region of the P. falciparum enzyme from those of its bacterial counterparts.
Collapse
Affiliation(s)
- Mili Kapoor
- *Molecular Biophysics Unit, Indian Institute of Science, Bangalore-560012, India
| | | | - Namita Surolia
- †Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore, India
- To whom correspondence should be addressed (e-mail )
| | - Avadhesha Surolia
- *Molecular Biophysics Unit, Indian Institute of Science, Bangalore-560012, India
| |
Collapse
|
32
|
Surolia A, Ramya T, Ramya V, Surolia N. 'FAS't inhibition of malaria. Biochem J 2004; 383:401-12. [PMID: 15315475 PMCID: PMC1133732 DOI: 10.1042/bj20041051] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2004] [Revised: 08/04/2004] [Accepted: 08/18/2004] [Indexed: 01/29/2023]
Abstract
Malaria, a tropical disease caused by Plasmodium sp., has been haunting mankind for ages. Unsuccessful attempts to develop a vaccine, the emergence of resistance against the existing drugs and the increasing mortality rate all call for immediate strategies to treat it. Intense attempts are underway to develop potent analogues of the current antimalarials, as well as a search for novel drug targets in the parasite. The indispensability of apicoplast (plastid) to the survival of the parasite has attracted a lot of attention in the recent past. The present review describes the origin and the essentiality of this relict organelle to the parasite. We also show that among the apicoplast specific pathways, the fatty acid biosynthesis system is an attractive target, because its inhibition decimates the parasite swiftly unlike the 'delayed death' phenotype exhibited by the inhibition of the other apicoplast processes. As the enzymes of the fatty acid biosynthesis system are present as discrete entities, unlike those of the host, they are amenable to inhibition without impairing the operation of the host-specific pathway. The present review describes the role of these enzymes, the status of their molecular characterization and the current advancements in the area of developing inhibitors against each of the enzymes of the pathway.
Collapse
Key Words
- antimalarial
- apicoplast
- fatty acid biosynthesis pathway
- malaria
- plasmodium falciparum
- triclosan
- acat, acyl-coa:acp transacylase
- acc, acetyl-coa carboxylase
- acp, acyl carrier protein
- cer, cerulenin
- fas, fatty acid synthase
- inh, isoniazid
- inha, enoyl-acp reductase of mycobacterium tuberculosis
- kas, β-oxoacyl-acp synthase (β-ketoacyl-acp synthase)
- mcat, malonyl-coa:acp transacylase
- orf, open reading frame
- pdh, pyruvate dehydrogenase
- pep, phosphoenolpyruvate
- pf, plasmodium falciparum
- tlm, thiolactomycin
Collapse
Affiliation(s)
- Avadhesha Surolia
- *Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560012, India
| | - T. N. C. Ramya
- *Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560012, India
| | - V. Ramya
- *Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560012, India
| | - Namita Surolia
- †Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India
| |
Collapse
|
33
|
Pidugu LS, Kapoor M, Surolia N, Surolia A, Suguna K. Structural basis for the variation in triclosan affinity to enoyl reductases. J Mol Biol 2004; 343:147-55. [PMID: 15381426 DOI: 10.1016/j.jmb.2004.08.033] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2004] [Revised: 08/04/2004] [Accepted: 08/10/2004] [Indexed: 11/17/2022]
Abstract
Bacteria synthesize fatty acids in a dissociated type pathway different from that in humans. Enoyl acyl carrier protein reductase, which catalyzes the final step of fatty acid elongation, has been validated as a potential anti-microbial drug target. Triclosan is known to inhibit this enzyme effectively. Precise characterization of the mode of triclosan binding is required to develop highly specific inhibitors. With this in view, interactions between triclosan, the cofactor NADH/NAD+ and the enzyme from five different species, one plant and four of microbial origin, have been examined in the available crystal structures. A comparison of these structures shows major structural differences at the substrate/inhibitor/cofactor-binding loop. The analysis reveals that the conformation of this flexible loop and the binding affinities of triclosan to each of these enzymes are strongly correlated.
Collapse
|
34
|
Kapoor M, Reddy C, Krishnasastry M, Surolia N, Surolia A. Slow-tight-binding inhibition of enoyl-acyl carrier protein reductase from Plasmodium falciparum by triclosan. Biochem J 2004; 381:719-24. [PMID: 15086316 PMCID: PMC1133881 DOI: 10.1042/bj20031821] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2003] [Revised: 03/05/2004] [Accepted: 04/16/2004] [Indexed: 11/17/2022]
Abstract
Triclosan is a potent inhibitor of FabI (enoyl-ACP reductase, where ACP stands for acyl carrier protein), which catalyses the last step in a sequence of four reactions that is repeated many times with each elongation step in the type II fatty acid biosynthesis pathway. The malarial parasite Plasmodium falciparum also harbours the genes and is capable of synthesizing fatty acids by utilizing the enzymes of type II FAS (fatty acid synthase). The basic differences in the enzymes of type I FAS, present in humans, and type II FAS, present in Plasmodium, make the enzymes of this pathway a good target for antimalarials. The steady-state kinetics revealed time-dependent inhibition of FabI by triclosan, demonstrating that triclosan is a slow-tight-binding inhibitor of FabI. The inhibition followed a rapid equilibrium step to form a reversible enzyme-inhibitor complex (EI) that isomerizes to a second enzyme-inhibitor complex (EI*), which dissociates at a very slow rate. The rate constants for the isomerization of EI to EI* and the dissociation of EI* were 5.49x10(-2) and 1x10(-4) s(-1) respectively. The K(i) value for the formation of the EI complex was 53 nM and the overall inhibition constant K(i)* was 96 pM. The results match well with the rate constants derived independently from fluorescence analysis of the interaction of FabI and triclosan, as well as those obtained by surface plasmon resonance studies [Kapoor, Mukhi, N. Surolia, Sugunda and A. Surolia (2004) Biochem. J. 381, 725-733].
Collapse
Affiliation(s)
- Mili Kapoor
- *Molecular Biophysics Unit, Indian Institute of Science, Bangalore-560012, India
| | | | | | - Namita Surolia
- ‡Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore, India
| | - Avadhesha Surolia
- *Molecular Biophysics Unit, Indian Institute of Science, Bangalore-560012, India
| |
Collapse
|